[1].钠-葡萄糖协同转运蛋白2抑制剂获益的研究进展及指南推荐050011；.河北省人民医院老年心血管内科，河北 石家庄 050051）[J].心血管病学进展,2021,(3):252-255，265.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
　Cardiology Department,The Third Hospital of Shijiazhuang City Affiliated to Hebei Medical University,Shijiazhuang 000,et al.Research Progress and Guideline Recommendations of Cardiovascular Benefits of SGLT-2 Inhibitors[J].Advances in Cardiovascular Diseases,2021,(3):252-255，265.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
点击复制

钠-葡萄糖协同转运蛋白2抑制剂获益的研究进展及指南推荐050011；.河北省人民医院老年心血管内科，河北 石家庄 050051）()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年3期
页码:
252-255，265
栏目:
出版日期:
2021-03-25

文章信息/Info

Title:
Research Progress and Guideline Recommendations of Cardiovascular Benefits of SGLT-2 Inhibitors
Author(s):
Cardiology Department; The Third Hospital of Shijiazhuang City Affiliated to Hebei Medical University; Shijiazhuang 050011; Hebei; China;2.Geriatric Cardiology Department; Hebei General Hospital; Shijiazhuang 050051; Hebei; China)
关键词:
尿病; 钠-葡萄糖协同转运蛋白2抑制剂
Keywords:
Type 2 diabetes; Cardiovascular diseaseSGLT-2 inhibitor
DOI:
10.16806/j.cnki.issn.1004-3934.2021.03.015
摘要:
心血管并发症是糖尿病患者最严重并发症治疗核心是在有效降糖的对各种危险因素进行，以降低相关死亡风险，改善患者预后。新降糖药钠-葡萄糖协同转运蛋白2抑制剂不仅可有效降糖，可显著降低风险，具有良好的安全性，为糖尿病合并患者的管理提供了理想选择。就钠-葡萄糖协同转运蛋白2抑制剂在获益的临床进展及指南推荐综述。
Abstract:
Cardiovascular complications are the most serious complication and the main cause of death and disability in patients with type 2 diabetes. The focus of treatment is reduc blood glucose effectively,while intervening various risk factors of cardiovascular diseases,to reduce the risk of death related to cardiovascular diseases and improve the prognosis of patients. The new oral hypoglycemic drug SGLT-2 inhibitor can not only reduce glucose effectively,but also significantly reduce the risk of cardiovascular diseases. At the same time, it has good safety and provides an ideal choice for the management of patients with cardiovascular diseases. This article reviews the clinical progress and guideline recommendations of SGLT-2 inhibitors in cardiovascular benefits

相似文献/References:

[1]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
　GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[2]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
　WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[3]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
　XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[4]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
　ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[5]张欣 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂相关心血管益处的可能潜在机制[J].心血管病学进展,2020,(9):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
　ZHANG Xin,GUO Yifang.Potential Mechanisms of Sodium-glucose Co-transporter 2 Inhibitor-related Cardiovascular Benefits[J].Advances in Cardiovascular Diseases,2020,(3):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
[6]和丽丽 左庆娟 张国瑞 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂使心力衰竭获益的作用机制[J].心血管病学进展,2020,(9):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
　HE Lili,ZUO Qingjuan,ZHANG Guorui,et al.Mechanism of Benefit of Sodium-glucose Co-transporter 2 Inhibitors in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
[7]杨宜恒 郑振中.钠-葡萄糖协同转运蛋白2抑制剂对于未合并2型糖尿病的心力衰竭患者治疗的研究进展[J].心血管病学进展,2021,(12):1093.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.009]
　YANG Yiheng,ZHENG Zhenzhong.Treatment of Sodium-Glucose Co-Transporter 2 Inhibitor in Patients with Heart Failure without Type 2 Diabetes[J].Advances in Cardiovascular Diseases,2021,(3):1093.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.009]
[8]张敏 龙开超 唐毅 刘君宇 彭建强.钠-葡萄糖协同转运蛋白2抑制剂使心力衰竭获益机制研究进展[J].心血管病学进展,2021,(12):1096.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.010]
　ZHANG Min,LONG Kaichao,TANG Yi,et al.Mechanism of the Benefit of Sodium-Glucose?o-Transporter 2 Inhibitors in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(3):1096.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.010]

更新日期/Last Update: 2021-06-16